Peginterferon-α-2a/ribavirin
1
Reactions 1422 - 6 Oct 2012 S Peginterferon-α-2a/ribavirin Thrombocytopenia and exacerbation of anaemia in an elderly patient: case report A 66-year-old man developed thrombocytopenia and exacerbation of anaemia while receiving peginterferon- α-2a and ribavirin. The man, whose history included diabetic nephropathy with chronic hepatitis C involvement, was admitted for viral elimination therapy. He had anaemia and reduced renal function on admission. He started receiving injections of peginterferon-α-2a 135 µg/week and ribavirin 400 mg/day [route not stated], and commenced double filtration plasmapheresis. After starting therapy, a decreased platelet count was observed [time to onset not stated]. This was thought to be due to peginterferon-α-2a. Seven days after starting peginterferon-α-2a, the dosage was reduced to 70 µg/week. The man subsequently developed exacerbation of anaemia, and ribavirin was withdrawn after 21 days of therapy. He continued to receive peginterferon-α-2a and plasmapheresis, and subsequently achieved sustained viral remission. Author comment: "Although the administration of [ribavirin] was discontinued 21 days after the beginning of therapy due to adverse effects, [sustained viral remission] could be achieved by a reduced dose of [peginterferon-α-2a] alone." Okuyama H, et al. A case of chronic hepatitis c with nephrotic diabetic nephropathy who achieved sustained viral remission by double-filtration plasmapheresis and interferon combination therapy. Internal Medicine 51: 1991-1995, No. 15, Aug 2012. Available from: URL: http://dx.doi.org/10.2169/ internalmedicine.51.7117 - Japan 803077906 1 Reactions 6 Oct 2012 No. 1422 0114-9954/10/1422-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Peginterferon-α-2a/ribavirin
Reactions 1422 - 6 Oct 2012
SPeginterferon-α-2a/ribavirin
Thrombocytopenia and exacerbation of anaemiain an elderly patient: case report
A 66-year-old man developed thrombocytopenia andexacerbation of anaemia while receiving peginterferon-α-2a and ribavirin.
The man, whose history included diabetic nephropathywith chronic hepatitis C involvement, was admitted for viralelimination therapy. He had anaemia and reduced renalfunction on admission. He started receiving injections ofpeginterferon-α-2a 135 µg/week and ribavirin 400 mg/day[route not stated], and commenced double filtrationplasmapheresis. After starting therapy, a decreased plateletcount was observed [time to onset not stated]. This wasthought to be due to peginterferon-α-2a.
Seven days after starting peginterferon-α-2a, the dosagewas reduced to 70 µg/week. The man subsequentlydeveloped exacerbation of anaemia, and ribavirin waswithdrawn after 21 days of therapy. He continued toreceive peginterferon-α-2a and plasmapheresis, andsubsequently achieved sustained viral remission.
Author comment: "Although the administration of[ribavirin] was discontinued 21 days after the beginning oftherapy due to adverse effects, [sustained viral remission]could be achieved by a reduced dose of [peginterferon-α-2a]alone."Okuyama H, et al. A case of chronic hepatitis c with nephrotic diabeticnephropathy who achieved sustained viral remission by double-filtrationplasmapheresis and interferon combination therapy. Internal Medicine 51:1991-1995, No. 15, Aug 2012. Available from: URL: http://dx.doi.org/10.2169/internalmedicine.51.7117 - Japan 803077906
1
Reactions 6 Oct 2012 No. 14220114-9954/10/1422-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
